LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 28

Search options

  1. Article: Retroaortic left renal vein associated to variations of liver vasculature and biliary system in a patient submitted to total pancreatectomy.

    Fancellu, Alessandro / Maiore, Mario / Grasso, Lavinia / Ferrara, Miriam / Porcu, Alberto

    Hepatobiliary & pancreatic diseases international : HBPD INT

    2023  

    Language English
    Publishing date 2023-11-07
    Publishing country Singapore
    Document type Letter
    ZDB-ID 2241386-8
    ISSN 1499-3872
    ISSN 1499-3872
    DOI 10.1016/j.hbpd.2023.11.003
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6313: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Meta-analysis of the prognostic impact of TP53 co-mutations in EGFR-mutant advanced non-small-cell lung cancer treated with tyrosine kinase inhibitors.

    Ferrara, Miriam Grazia / Belluomini, Lorenzo / Smimmo, Annafrancesca / Sposito, Marco / Avancini, Alice / Giannarelli, Diana / Milella, Michele / Pilotto, Sara / Bria, Emilio

    Critical reviews in oncology/hematology

    2023  Volume 184, Page(s) 103929

    Abstract: Purpose: To assess the prognostic impact of TP53 mutations in EGFR-mutant advanced NSCLC patients treated with TKIs.: Methods: Studies exploring the clinical outcomes of EGFR mutant/TP53 wild-type versus EGFR/TP53 co-mutant patients treated with TKIs ...

    Abstract Purpose: To assess the prognostic impact of TP53 mutations in EGFR-mutant advanced NSCLC patients treated with TKIs.
    Methods: Studies exploring the clinical outcomes of EGFR mutant/TP53 wild-type versus EGFR/TP53 co-mutant patients treated with TKIs were selected. Data were cumulated by adopting a fixed and random-effect model.
    Results: Overall, 29 trials were eligible. The PFS analysis showed that TP53 co-mutant group has shorter PFS versus EGFR mutant/TP53 wild-type group (HR = 1.67, 95% CI 1.51-1.83, heterogeneity I
    Conclusions: TP53 mutations represent a clinically relevant mechanism of resistance to EGFR-TKIs, regardless of their generation. A personalized therapeutical approach should be explored in dedicated clinical trials.
    MeSH term(s) Humans ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/genetics ; Prognosis ; Lung Neoplasms/drug therapy ; Lung Neoplasms/genetics ; Lung Neoplasms/chemically induced ; Tyrosine Kinase Inhibitors ; ErbB Receptors ; Mutation ; Protein Kinase Inhibitors/therapeutic use ; Tumor Suppressor Protein p53/genetics
    Chemical Substances Tyrosine Kinase Inhibitors ; ErbB Receptors (EC 2.7.10.1) ; Protein Kinase Inhibitors ; TP53 protein, human ; Tumor Suppressor Protein p53 ; EGFR protein, human (EC 2.7.10.1)
    Language English
    Publishing date 2023-02-10
    Publishing country Netherlands
    Document type Meta-Analysis ; Journal Article ; Review
    ZDB-ID 605680-5
    ISSN 1879-0461 ; 0737-9587 ; 1040-8428
    ISSN (online) 1879-0461
    ISSN 0737-9587 ; 1040-8428
    DOI 10.1016/j.critrevonc.2023.103929
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1931: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Evaluating Stress in Dogs Involved in Animal-Assisted Interventions

    Corsetti, Sara / Ferrara, Miriam / Natoli, Eugenia

    Animals. 2019 Oct. 19, v. 9, no. 10

    2019  

    Abstract: Animal-assisted interventions (AAIs) are co-therapies in which the animal is an integral and active part of the treatment process. Dogs are widely involved in AAI projects, but little data are available to determine if AAI sessions are a source of stress ...

    Abstract Animal-assisted interventions (AAIs) are co-therapies in which the animal is an integral and active part of the treatment process. Dogs are widely involved in AAI projects, but little data are available to determine if AAI sessions are a source of stress for the dogs. Understanding the emotional state of animals and highlighting any signal of stress is crucial maintaining the wellness of the animals and in enhancing the probability of success of the AAI. The purpose of this study is to assess if dogs present signs of stress during animal assisted therapies sessions. The sample consisted of nine dogs, belonging to the members of the A.N.U.C.S.S. (the National Association for the Use of Dogs for Social Aims) association. Dogs lived with their owners and their health was checked by a vet once a week. Patients involved in the AAI project had disabilities due to mental disorder and/or psychomotor problems. During the therapeutic sessions, patients had to guide the dog along facilitated agility routes and/or perform the activities of cuddling and brushing the dog. When a dog accomplished a task, the patient gave him/her a reward (throwing a ball or a biscuit). Dogs were observed for a total of 174 h, 47 h before, 81 h during, and 46 h after AAI sessions. Each session of observation lasted 10–30 min. The differences of behavioural patterns in the three contexts were analysed by mean of the non-parametric Friedman test. Dogs never showed aggressive and stereotyped behaviour; the level of anxious behaviour was low and similar in all three kinds of sessions. During therapeutic sessions, attention, affiliative behavioural patterns, and sniffing behaviour increased. The highest level of attention of dogs was directed toward their conductor, rather than to the patient and to the other operator present. The results suggest that the amount of work dogs went through was adequate and that dogs did not show behavioural signs of stress.
    Keywords animal assisted therapy ; behavior disorders ; dogs ; patients ; probability ; stereotyped behavior
    Language English
    Dates of publication 2019-1019
    Publishing place Multidisciplinary Digital Publishing Institute
    Document type Article
    ISSN 2076-2615
    DOI 10.3390/ani9100833
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  4. Article: Evaluating Stress in Dogs Involved in Animal-Assisted Interventions.

    Corsetti, Sara / Ferrara, Miriam / Natoli, Eugenia

    Animals : an open access journal from MDPI

    2019  Volume 9, Issue 10

    Abstract: Animal-assisted interventions (AAIs) are co-therapies in which the animal is an integral and active part of the treatment process. Dogs are widely involved in AAI projects, but little data are available to determine if AAI sessions are a source of stress ...

    Abstract Animal-assisted interventions (AAIs) are co-therapies in which the animal is an integral and active part of the treatment process. Dogs are widely involved in AAI projects, but little data are available to determine if AAI sessions are a source of stress for the dogs. Understanding the emotional state of animals and highlighting any signal of stress is crucial maintaining the wellness of the animals and in enhancing the probability of success of the AAI. The purpose of this study is to assess if dogs present signs of stress during animal assisted therapies sessions. The sample consisted of nine dogs, belonging to the members of the A.N.U.C.S.S. (the National Association for the Use of Dogs for Social Aims) association. Dogs lived with their owners and their health was checked by a vet once a week. Patients involved in the AAI project had disabilities due to mental disorder and/or psychomotor problems. During the therapeutic sessions, patients had to guide the dog along facilitated agility routes and/or perform the activities of cuddling and brushing the dog. When a dog accomplished a task, the patient gave him/her a reward (throwing a ball or a biscuit). Dogs were observed for a total of 174 h, 47 h before, 81 h during, and 46 h after AAI sessions. Each session of observation lasted 10-30 min. The differences of behavioural patterns in the three contexts were analysed by mean of the non-parametric Friedman test. Dogs never showed aggressive and stereotyped behaviour; the level of anxious behaviour was low and similar in all three kinds of sessions. During therapeutic sessions, attention, affiliative behavioural patterns, and sniffing behaviour increased. The highest level of attention of dogs was directed toward their conductor, rather than to the patient and to the other operator present. The results suggest that the amount of work dogs went through was adequate and that dogs did not show behavioural signs of stress.
    Language English
    Publishing date 2019-10-19
    Publishing country Switzerland
    Document type Journal Article
    ISSN 2076-2615
    ISSN 2076-2615
    DOI 10.3390/ani9100833
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  5. Article ; Online: Long-term survivors with immunotherapy in advanced NSCLC: is 'cure' within reach?

    Monteverdi, Sara / Vita, Emanuele / Sartori, Giulia / Ferrara, Miriam Grazia / D'Argento, Ettore / Tortora, Giampaolo / Milella, Michele / Bria, Emilio / Pilotto, Sara

    Translational cancer research

    2022  Volume 9, Issue 2, Page(s) 409–414

    Language English
    Publishing date 2022-01-20
    Publishing country China
    Document type Editorial ; Comment
    ZDB-ID 2901601-0
    ISSN 2219-6803 ; 2218-676X
    ISSN (online) 2219-6803
    ISSN 2218-676X
    DOI 10.21037/tcr.2019.12.82
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Maintenance or consolidation therapy in small-cell lung cancer: an updated systematic review and meta-analysis.

    Belluomini, Lorenzo / Pilotto, Sara / Avancini, Alice / Insolda, Jessica / Sposito, Marco / Menis, Jessica / Ciccarese, Chiara / Iacovelli, Roberto / Ferrara, Miriam Grazia / Milella, Michele / Bria, Emilio / Rossi, Antonio

    Seminars in oncology

    2022  Volume 49, Issue 5, Page(s) 389–393

    Abstract: We performed an updated meta-analysis to explore the role of maintenance therapy in SCLC. Clinical trials with randomization to maintenance/consolidation (V) placebo or observation or best supportive care in SCLC, both extended and limited disease were ... ...

    Abstract We performed an updated meta-analysis to explore the role of maintenance therapy in SCLC. Clinical trials with randomization to maintenance/consolidation (V) placebo or observation or best supportive care in SCLC, both extended and limited disease were searched from January 2009 to March 2022. The hazard ratios (HR) for progression-free survival (PFS) and overall survival (OS) with the relative 95% confidence interval (CI) were extracted from each study. Summary HR was calculated using random- or fixed-effects models, depending on the heterogeneity of the included studies. A total of 9 studies were identified. Neither PFS nor OS were improved with maintenance/consolidation (PFS: random-effect; HR 0.93; 95% CI 0.71-1.21; P=0.10; OS: fixed-effect; HR 0.98; 95% CI 0.89-1.08; P=0.14). Among the different strategies, immunotherapy maintenance showed a significantly decreased risk of progression (V)standard of care (random-effect; HR 0.80; 95% CI 0.66-0.97; P=0.03). The current updated meta-analysis did not demonstrate a benefit of maintenance/consolidation therapy in SCLC, with only a PFS benefit for immunotherapy approach.
    MeSH term(s) Humans ; Lung Neoplasms/drug therapy ; Consolidation Chemotherapy ; Immunotherapy ; Progression-Free Survival
    Language English
    Publishing date 2022-09-23
    Publishing country United States
    Document type Meta-Analysis ; Systematic Review ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 189220-4
    ISSN 1532-8708 ; 0093-7754
    ISSN (online) 1532-8708
    ISSN 0093-7754
    DOI 10.1053/j.seminoncol.2022.09.001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1348: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Selpercatinib in RET-fusion positive metastatic non-small cell lung cancer: achievements and gray areas.

    Belluomini, Lorenzo / Avancini, Alice / Pasqualin, Luca / Insolda, Jessica / Sposito, Marco / Menis, Jessica / Tregnago, Daniela / Trestini, Ilaria / Ferrara, Miriam Grazia / Bria, Emilio / Milella, Michele / Pilotto, Sara

    Expert review of anticancer therapy

    2022  Volume 22, Issue 8, Page(s) 785–794

    Abstract: Introduction: Selpercatinib is a RET selective tyrosine kinase inhibitor with nanomolar potency against diverse RET alterations, including fusions, activating point mutations, and acquired resistance mutations. Rearranged during transfection (RET) gene ... ...

    Abstract Introduction: Selpercatinib is a RET selective tyrosine kinase inhibitor with nanomolar potency against diverse RET alterations, including fusions, activating point mutations, and acquired resistance mutations. Rearranged during transfection (RET) gene is a validated target in non-small-cell lung cancer (NSCLC). Selpercatinib is currently approved for adult patients with metastatic RET fusion-positive NSCLC.
    Areas covered: This review summarizes the efficacy and safety data of selpercatinib in the treatment landscape of RET fusion-positive NSCLC.
    Expert opinion: Globally considered, selpercatinib is an optimal treatment choice, in terms of both (systemic and intracranial) efficacy and safety, in patients affected by advanced NSCLC harboring RET fusions as a
    MeSH term(s) Adult ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/pathology ; Humans ; Lung Neoplasms/drug therapy ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; Protein Kinase Inhibitors/pharmacology ; Proto-Oncogene Proteins c-ret/genetics ; Pyrazoles ; Pyridines
    Chemical Substances Protein Kinase Inhibitors ; Pyrazoles ; Pyridines ; selpercatinib (CEGM9YBNGD) ; Proto-Oncogene Proteins c-ret (EC 2.7.10.1) ; RET protein, human (EC 2.7.10.1)
    Language English
    Publishing date 2022-06-27
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2112544-2
    ISSN 1744-8328 ; 1473-7140
    ISSN (online) 1744-8328
    ISSN 1473-7140
    DOI 10.1080/14737140.2022.2093190
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5907: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article: A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done.

    Belluomini, Lorenzo / Dodi, Alessandra / Caldart, Alberto / Kadrija, Dzenete / Sposito, Marco / Casali, Miriam / Sartori, Giulia / Ferrara, Miriam Grazia / Avancini, Alice / Bria, Emilio / Menis, Jessica / Milella, Michele / Pilotto, Sara

    Translational lung cancer research

    2021  Volume 10, Issue 7, Page(s) 3369–3384

    Abstract: Objective: In this review, we aim to collect and discuss available data about the role and composition of tumor microenvironment (TME) in oligometastatic (OMD) and oligoprogressive (OPD) non-small cell lung cancer (NSCLC). Furthermore, we aim to ... ...

    Abstract Objective: In this review, we aim to collect and discuss available data about the role and composition of tumor microenvironment (TME) in oligometastatic (OMD) and oligoprogressive (OPD) non-small cell lung cancer (NSCLC). Furthermore, we aim to summarize the ongoing clinical trials evaluating as exploratory objective the TME composition, through tissue and/or blood samples, in order to clarify whether TME and its components could explain, at least partially, the oligometastatic/oligoprogressive process and could unravel the existence of predictive and/or prognostic factors for local ablative therapy (LAT).
    Background: OMD/OPD NSCLC represent a heterogeneous group of diseases. Several data have shown that TME plays an important role in tumor progression and therefore in treatment response. The crucial role of several types of cells and molecules such as immune cells, cytokines, integrins, protease and adhesion molecules, tumor-associated macrophages (TAMs) and mesenchymal stem cells (MSCs) has been widely established. Due to the peculiar activation of specific pathways and expression of adhesion molecules, metastatic cells seem to show a tropism for specific anatomic sites (the so-called "seed and soil" hypothesis). Based on this theory, metastases appear as a biologically driven process rather than a random release of cancer cells. Although the role and the function of TME at the time of progression in patients with NSCLC treated with tyrosine-kinase inhibitors and immune checkpoint inhibitors (ICIs) have been investigated, limited data about the role and the biological meaning of TME are available in the specific OMD/OPD setting.
    Methods: Through a comprehensive PubMed and ClinicalTrials.gov search, we identified available and ongoing studies exploring the role of TME in oligometastatic/oligoprogressive NSCLC.
    Conclusions: Deepening the knowledge on TME composition and function in OMD/OPD may provide innovative implications in terms of both prognosis and prediction of outcome in particular from local treatments, paving the way for future investigations of personalized approaches in both advanced and early disease settings.
    Language English
    Publishing date 2021-08-25
    Publishing country China
    Document type Journal Article ; Review
    ZDB-ID 2754335-3
    ISSN 2226-4477 ; 2218-6751
    ISSN (online) 2226-4477
    ISSN 2218-6751
    DOI 10.21037/tlcr-20-1134
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article: Exploiting

    Di Noia, Vincenzo / D'Argento, Ettore / Pilotto, Sara / Ferrara, Miriam Grazia / Milella, Michele / Tortora, Giampaolo / Bria, Emilio

    Translational lung cancer research

    2019  Volume 7, Issue Suppl 4, Page(s) S312–S317

    Language English
    Publishing date 2019-01-30
    Publishing country China
    Document type Editorial ; Comment
    ZDB-ID 2754335-3
    ISSN 2226-4477 ; 2218-6751
    ISSN (online) 2226-4477
    ISSN 2218-6751
    DOI 10.21037/tlcr.2018.12.08
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Concurrent Nivolumab and Metformin in Diabetic Cancer Patients: Is It Safe and More Active?

    Ciccarese, Chiara / Iacovelli, Roberto / Buti, Sebastiano / Primi, Francesca / Astore, Serena / Massari, Francesco / Ferrara, Miriam Grazia / Palermo, Giuseppe / Foschi, Nazario / Iacovelli, Valerio / Rossi, Ernesto / Schinzari, Giovanni / Bove, Pierluigi / Bassi, Pierfrancesco / Bria, Emilio / Tortora, Giampaolo

    Anticancer research

    2022  Volume 42, Issue 3, Page(s) 1487–1493

    Abstract: Background/aim: Recent evidence suggests potential synergistic antitumor effects of the combination of programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) immune checkpoint inhibitors with the oral hypoglycemic agent metformin. The aim of this ... ...

    Abstract Background/aim: Recent evidence suggests potential synergistic antitumor effects of the combination of programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) immune checkpoint inhibitors with the oral hypoglycemic agent metformin. The aim of this study was to investigate the safety and activity of metformin combined with nivolumab in diabetic cancer patients.
    Patients and methods: Patients with advanced melanoma, renal cell carcinoma or lung cancer receiving nivolumab with concurrent diabetes treated with metformin were retrospectively collected. The primary endpoint was the safety of nivolumab plus metformin combination.
    Results: We collected 40 patients with solid tumors who received metformin for concomitant diabetes and nivolumab as anticancer therapy in four Italian Hospitals. The concomitant use of nivolumab and metformin was well tolerated; adverse events (AEs) of any grade occurred in 75% of patients (mainly fatigue, pruritus, rash, and asthenia). Grade 3 AEs occurred only in 20% of cases; no grade 4 AEs were observed. A statistically significant correlation was found between higher doses of metformin (>1,000 mg daily) and longer progression-free survival (p=0.021), overall survival (p=0.037) and higher overall response rate.
    Conclusion: The combination of nivolumab and metformin was safe and might have an antitumor activity, supporting further investigations on the synergistic antitumor effect of this combination.
    MeSH term(s) Aged ; B7-H1 Antigen/antagonists & inhibitors ; Diabetes Mellitus, Type 2/diagnosis ; Diabetes Mellitus, Type 2/drug therapy ; Diabetes Mellitus, Type 2/mortality ; Female ; Humans ; Hypoglycemic Agents/adverse effects ; Hypoglycemic Agents/therapeutic use ; Immune Checkpoint Inhibitors/adverse effects ; Immune Checkpoint Inhibitors/therapeutic use ; Italy ; Male ; Metformin/adverse effects ; Metformin/therapeutic use ; Neoplasms/diagnosis ; Neoplasms/drug therapy ; Neoplasms/immunology ; Neoplasms/mortality ; Nivolumab/adverse effects ; Nivolumab/therapeutic use ; Progression-Free Survival ; Retrospective Studies ; Time Factors
    Chemical Substances B7-H1 Antigen ; CD274 protein, human ; Hypoglycemic Agents ; Immune Checkpoint Inhibitors ; Nivolumab (31YO63LBSN) ; Metformin (9100L32L2N)
    Language English
    Publishing date 2022-02-22
    Publishing country Greece
    Document type Journal Article ; Multicenter Study
    ZDB-ID 604549-2
    ISSN 1791-7530 ; 0250-7005
    ISSN (online) 1791-7530
    ISSN 0250-7005
    DOI 10.21873/anticanres.15620
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1642: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top